Other
AstraZeneca buys US biotech firm CinCor
Anglo-Swedish pharmaceuticals giant AstraZeneca on Monday agreed to buy US biotech company CinCor for $1.8 billion, expanding further into the field of heart and kidney drugs.
Jan 9, 2023
0
2
News tagged with takeover
Other
Takeda hikes Shire takeover bid to almost $61 bn
Japanese drugs firm Takeda on Friday upped its takeover bid to $60.7 billion (49 billion euros) for Irish-based peer Shire, which has already rejected its previous three overtures.
Apr 20, 2018
0
0
Medications
AstraZeneca doubles profits; warns of lower drug sales
British pharmaceuticals giant AstraZeneca on Thursday said its net profits more than doubled in 2015, adding it expects lower sales this year on US patent expiry of cholesterol treatment Crestor.
Feb 4, 2016
0
0
Medications
AstraZeneca says in talks with Acerta Pharma
British phamaceuticals giant AstraZeneca revealed Monday that it was in discussions over a deal with cancer drug maker Acerta Pharma.
Dec 14, 2015
0
1
Medications
Perrigo to go it alone; shareholders reject $26B Mylan bid (Update)
Shareholders of the drugmaker Perrigo shut the door on a $26-billion hostile takeover bid from Mylan.
Nov 13, 2015
0
3
Medications
Mylan takes takeover bid to Perrigo shareholders
Pharmaceutical company Mylan said Tuesday that it would take its offer to buy Perrigo directly to Perrigo shareholders following refusals by the company's management to engage in merger talks.
Sep 8, 2015
0
7
Medications
Big pharma deals: Mylan raises bid for Perrigo to $35.6 bn
Generic drug company Mylan raised its bid for a second time for Perrigo on Wednesday, offering $35.6 billion for the over-the-counter giant.
Apr 29, 2015
0
1
Other
AstraZeneca profits tumble in third quarter
British pharmaceuticals group AstraZeneca announced on Thursday a slump in quarterly profits, in part on higher investment costs, but raised its outlook for full-year revenues.
Nov 6, 2014
0
0
Other
Valeant: We'll bump Allergan offer to $200 a share
The Canadian drugmaker Valeant said it would be willing to raise its takeover bid for Allergan by almost 12 percent, which would mean $200 or more per share for the maker of Botox.
Oct 27, 2014
0
0
Other
AbbVie to pay Shire $1.64B fee over nixed merger
AbbVie is walking away from its proposed $55 billion takeover bid of Shire and has agreed to pay the rival drugmaker a $1.64 billion breakup fee.
Oct 20, 2014
0
0
